Saturday January 18, 2020
Home Lead Story Tibetan Monk ...

Tibetan Monk Sentenced for The Second Time by Chinese Authorities in Tibet

He was kept under incommunicado detention since then and neither his family members nor the monastery had much information

0
//
Tibetan, Monk, Chinese
In July last year, Kirti Monastery’s monk Lobsang Dorje aged about 36 years was picked up by the Chinese police authorities from his monastic quarters in the middle of the night on suspicion of contacting with the outside world.

By Vijyender Sharma

 A Tibetan monk from Ngaba county’s Kirti Monastery who was arrested more than a year ago was sentenced to 3 years in prison by Chinese authorities  as per information received by Tibetan Government in exile at Dharmshala. Tibetan

In July last year, Kirti Monastery’s monk Lobsang Dorje aged about 36 years was picked up by the Chinese police authorities from his monastic quarters in the middle of the night on suspicion of contacting with the outside world. He was kept under incommunicado detention since then and neither his family members nor the monastery had much information about his whereabouts until the recent sentencing. According to Lobsang Yeshi and Kanyag Tsering, monks from branch of Kirti Monastery based in Dharamshala, Lobsang Dorje was born in the Ngaba County’s Chukle Gabma village and joined Kirti Monastery in Tibet at a very young age. His father’s name is Sangri.

This is the second sentencing of Lobsang Dorje. He was earlier arrested on 23 May 2008 for showing disrespect to the “patriotic re-education” which was being imposed on the Kirti monastery. He was sentenced to two years imprisonment then.

Tibetan, Monk, Chinese
A Tibetan monk from Ngaba county’s Kirti Monastery who was arrested more than a year ago was sentenced to 3 years in prison by Chinese authorities as per information received by Tibetan Government in exile at Dharmshala. Pixabay

The health conditions of Lobsang Dorje is yet unknown. It is a common practice of torturing Tibetan political prisoners especially while they are in incommunicado detention. Moreover, former political prisoners are especially in a vulnerable position as they are under continuous surveillance by the authorities and are picked up from their residence at odd hours on mere suspicions as was the case with Lobsang Dorje.

Also Read- Kenya Third African Country to Roll Out World’s First Malaria Vaccine

Moreover, the charges for sentencing Lobsang Dorje are not yet known. China has frequently abused and misused the law, particularly Article 103 (2) of the Chinese Criminal law on “incitement to separatism” to suppress freedom of expression, religion, assembly and association and the cultural rights of the Tibetans. Recently Five UN Special Rapporteurs wrote to China asking about a group of Tibetans arrested for celebrating the Dalai Lama’s 80th birthday.

Next Story

Chinese Alzheimer’s Drug to Undergo Global Clinical Trials

In the last test, a total of 818 participants from 34 leading hospitals in China took 450 mg GV-971 orally twice a day for a treatment period of nine months, which proved safe and effective in improving cognition

0
In Alzheimer's disease, patients start losing memory. Pixabay

An innovative Chinese Alzheimer’s drug extracted from brown algae is set to go through clinical trials on 2,000 patients overseas this year.

The orally administered drug GV-971 will be tested in 200 clinical centers in North America, the European Union, Eastern Europe, Asia Pacific and other places, according to Green Valley Pharmaceutical Company, one of the drug’s co-developers.

China has already approved the drug.

Green Valley Pharmaceutical will complete the global clinical trials in 2024 and submit the New Drug Application to the US Food and Drug Administration and European Medicines Agency in 2025, Xinhua reported.

GV-971 was jointly developed by the Shanghai Institute of Materia Medica under the Chinese Academy of Sciences (CAS), Ocean University of China and Green Valley, after a 22-year study.

Alzheimer's
A lady suffering from Alzheimer’s. Flickr

The results of the mechanism of action study were published in the international journal Cell Research in September 2019, saying that the drug works by modifying gut bacteria to ultimately reduce brain inflammation in mice that were genetically engineered to have the disease.

It was approved for marketing last November by China’s National Medical Products Administration, which said the GV-971 “can improve cognition in patients with mild to moderate Alzheimer’s disease (AD).”

Also Read: NASA Loses Contact with Satellite to Study Distant Planets: Report

According to researchers, apart from animal experiments, more than 1,100 Chinese Alzheimer’s disease patients participated in clinical trials before the drug hit the market.

In the last test, a total of 818 participants from 34 leading hospitals in China took 450 mg GV-971 orally twice a day for a treatment period of nine months, which proved safe and effective in improving cognition.

“Because of its effectiveness on Chinese patients, we expect this drug to benefit more people in the rest of the world,” said Lyu Songtao, Chairman of the Shanghai-based pharmaceutical company. (IANS)